| News

T3 Pharmaceuticals wins W.A. de Vigier Award

28.05.2019

T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer therapy using bacteria.

T3 Pharma (img: Universität Basel, Basile Bornand)

T3 Pharmaceuticals is among the ten winners of this year’s W.A. de Vigier Award. The Basel startup impressed the jury with its targeted cancer therapy. T3 Pharmaceuticals employ living bacteria that have the capacity to specifically find and grow in solid tumors, where the bacteria serve as efficient factories for therapeutically active proteins. The startup was founded in 2015 out of a research project at the Biozentrum of the University of Basel. T3 Pharmaceuticals is a portfolio company of BaseLaunch.

With annual prize money of 500,000 Swiss francs, the W.A. de Vigier promotional award is the oldest and most financially significant award for startups in Switzerland. To mark its 30th anniversary, the W.A. de Vigier Foundation selected twice as many startups to win the award this year. What’s more, 60 startups were able to pitch to the jury rather than the usual 16. This year’s prize money also increased to 750,000 francs overall, with some of the funds being contributed by former award winners.

“I am particularly pleased that former winners contributed to this year’s prize money. I hope that in the future our alumni will increasingly partner up with each other to help established companies remain innovative and pave the way for young startups to enter the market,” said Regula Buob, Managing Director of the W.A. de Vigier Foundation. This is all in the spirit of the founding father Bill de Vigier.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.